DAILY PROGRAM

Standard Time: GMT +09:00, Seoul/Tokyo

ROOM A

08:00-08:10

Opening

08:10-08:40

Satellite Symposium I (A). [Lilly]

Tae Min Kim (Seoul National Univ.)

08:10-08:40

How to Optimize Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer, Focusing on RET Alteration

Dae Ho Lee (Univ. of Ulsan)

08:40-08:50

Break

08:50-09:50

Session I (A). Lung Cancer Screening Update: Who, When, and How

Yeun-Chung Chang (National Taiwan Univ., Taiwan), Tae Jung Kim (Sungkyunkwan Univ.)

08:50-09:05

Lung Cancer Screening in Korea

Hyae Young Kim (National Cancer Center)

09:05-09:20

Lung Cancer Screening in Taiwan

Yeun-Chung Chang (National Taiwan Univ., Taiwan)

09:20-09:35

Lung Cancer Screening in the US

Jared Christensen (Duke Univ., USA)

09:35-09:50

Lung Cancer Screening in Europe (or Italy)

Mario Silva (Univ. of Parma, Italy)

09:50-10:00

Coffee Break

10:00-11:00

Session II (A). Recent Advance and Debate in Mediastinal Staging

Chair: Seung Hun Jang (Hallym Univ.), Yeon Wook Kim (Seoul National Univ.)

10:00-10:20

Is PET-CT Sufficient for Mediastinal Staging?

Julian M.M. Rogasch (Charité Universitätsmedizin Berlin, Germany)

10:20-10:40

Are Biopsy Negative Lymph Nodes on EBUS/EUS Truly Negative?

Jaeyoung Cho (Seoul National Univ.)

10:40-11:00

Should We Restage the Mediastinum Invasively after Neoadjuvant Chemo-Immunotherapy?

Jung Seop Eom (Pusan National Univ.)

11:00-11:15

Coffee Break

11:15-11:55

Plenary Session

Chair: Myung-Ju Ahn (Sungkyunkwan Univ.)

11:15-11:55

Identifying Predictive Biomarkers of Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Justin F Gainor (Massachusetts General Hospital, USA)

11:55-12:35

Luncheon Symposium I. [MSD]

Chair: Sang-We Kim (Univ. of Ulsan)

11:55-12:35

Long-Term Benefit and Beyond Current Role of Pembrolizumab Combination in Lung Cancer

James Chih-Hsin Yang (National Taiwan Univ., Taiwan)

12:35-12:50

Coffee Break

12:50-14:10

Session III (A). Small-Cell Lung Cancer Recent Update

Chair: Chen-Liang Tsai (Tri-Service General Hospital, Taiwan), Hyo Sup Shim (Yonsei Univ.)

12:50-13:15

Molecular Subtypes of Small Cell Lung Cancer

Tae Min Kim (Seoul National Univ.)

13:15-13:40

Advances of Systemic Treatment in Small-Cell Lung Cancer

Chen-Liang Tsai (Tri-Service General Hospital, Taiwan)

13:40-14:05

Future Strategies for Treatment Development

Terufumi Kato (Kanagawa Cancer Center, Japan)

14:05-14:10

Discussion

14:10-14:20

Coffee break

14:20-15:40

Session IV (A). EGFR Mutant Non-Small Cell Lung Cancer

Chair: Julia Rotow (Dana Farber Cancer Institute, USA), Jae Cheol Lee (Univ. of Ulsan)

14:20-14:40

Current Status of Treatment for EGFR Non-Small-Cell Lung Cancer

Lecia V. Sequist (Massachusetts General Hospital Cancer Center, USA)

14:40-15:00

In-Depth Review of Mechanisms of Resistance

Masahiro Tsuboi (National Cancer Center Hospital East, Japan)

15:00-15:20

Therapeutic Strategies Using Novel Targeted Agents

Yu Jung Kim (Seoul National Univ.)

15:20-15:40

Role of Immuno-Oncology in EGFR Mutant Non-Small-Cell Lung Cancer

Julia Rotow (Dana Farber Cancer Institute, USA)

15:40-15:50

Coffee Break

15:50-16:20

Satellite Symposium II (A). [AstraZeneca]

Chair: Dong-Wan Kim (Seoul National Univ.)

15:50-16:20

Osimertinib : The Backbone Therapy for EGFRm Non-Small Cell Lung Cancer Patients in Early to Advanced Stage

Beung Chul Ahn (National Cancer Center)

ROOM B

08:10-08:40

Satellite Symposium I (B). [Novartis]

Chair: Gyeong-Won Lee(Gyeongsang National Univ.)

08:10-08:40

Current Therapeutic Strategies in Patients with BRAF Mutant Non-Small Cell Lung Cancer

Shinkyo Yoon (Univ. of Ulsan)

08:40-08:50

Break

08:50-09:50

Session I (B). Novel Omics in Lung Cancer

Chair: Yasushi Yatabe (National Cancer Center, Japan), Seung Yeon Ha (Gachon Univ.)

08:50-09:10

Multiomics Analysis of Korean Non-Small Cell Lung Cancer Identifies Distinct Molecular Subtypes

Se Jin Jang (Univ. of Ulsan)

09:10-09:30

Molecular Landscape of Mucinous Carcinoma

Yasushi Yatabe (National Cancer Center, Japan)

09:30-09:50

Molecular Characterisation of Small-Cell Lung Cancer and Other NE Tumors

Yoon La Choi (Sungkyunkwan Univ.)

09:50-10:00

Coffee Break

10:00-11:00

Session II (B). Debate in PD-L1 High Lung Cancer

Chair: In-Jae Oh (Chonnam National Univ.), Shinkyo Yoon (Univ. of Ulsan)

10:00-10:20

PD-L1 High Lung Cancer in Elderly and Fragile Patients

Jin-Soo Kim (Seoul National Univ.)

10:20-10:40

PD-L1 High Lung Cancer in Patients with Actionable Driver Oncogenes

Ying-Chun Lo (Mayo Clinic, USA)

10:40-11:00

New Strategy of Predicting Imaging Biomarker for Lung Cancer

Hongyoon Choi (Seoul National Univ.)

11:00-11:15

Coffee Break

11:15-11:55

Plenary Session

Chair: Myung-Ju Ahn (Sungkyunkwan Univ.)

11:15-11:55

Identifying Predictive Biomarkers of Response to Checkpoint Inhibitors in NSCLC

Justin F Gainor (Massachusetts General Hospital, USA)

11:55-12:35

Luncheon Symposium I. [MSD]

Chair: Sang-We Kim (Univ. of Ulsan)

11:55-12:35

Long-Term Benefit and Beyond Current Role of Pembrolizumab Combination in Lung Cancer

James Chih-Hsin Yang (National Taiwan Univ., Taiwan)

12:35-12:50

Coffee break

12:50-14:10

Session III (B). Radiotherapy Update

Chair: Hong-Gyun Wu (Seoul National Univ.), Yoo-Kang Kwak (The Catholic Univ. of Korea)

12:50-13:10

Update of FLASH Radiotherapy, Especially in Preclinical Studies

Jean Bourhis (Univ. of Lausanne, Switzerland)

13:10-13:30

Update of Carbon Ion Therapy

Hong In Yoon (Yonsei Univ.)

13:30-13:50

Update of Proton Beam Therapy

Yang-Gun Suh (National Cancer Center)

13:50-14:10

Application of Continuous Positive Airway Pressure for Respiratory Motion Management

Jooho Lee (Seoul National Univ.)

14:10-14:20

Coffee break

14:20-15:40

Session IV (B). Ongoing Issues in Radiotherapy

Chair: Peter S.N. van Rossum (Amsterdam Univ. Medical Centers, The Netherlands), Song Si Yeol (Univ. of Ulsan)

14:20-14:40

When Does Post-Operative Radiotherapy Provide a Benefit?

Yeonsil Kim (The Catholic Univ. of Korea)

14:40-15:00

When Does Post-Operative Radiotherapy Not Provide a Benefit?

Rafal Dziadziuszko (Medical Univ. of Gdańsk Poland, Poland)

15:00-15:20

Prophylactic Cranial Irradiation for Patients with Limited-Disease Small-Cell Lung Cancer: Pros.

Peter S.N. van Rossum (Amsterdam Univ. Medical Centers, The Netherlands)

15:20-15:40

Prophylactic Cranial Irradiation for Patients with Limited-Disease Small-Cell Lung Cancer: Cons.

Byoung Hyuck Kim (Seoul National Univ.)

15:40-15:50

Coffee break

15:50-16:20

Satellite Symposium II (B). [Pfizer]

Chair: Jin Hyoung Kang (The Catholic Univ. of Korea)

15:50-16:20

Clinical Implications of ALK Positive NSCLC Treatment: Focusing on Lorlatinib’s Efficacy and Safety Profile

Sun Min Lim (Yonsei Univ.)

ROOM C

08:10-08:40

Satellite Symposium I (C). [Janssen]

Chair: Bhumsuk Keam (Seoul National Univ.)

08:10-08:40

Unveiling RYBREVANT’s Potential: Updated Clinical Insights and Real-World Practice

Sun Min Lim (Yonsei Univ.)

08:40-08:50

Break

08:50-09:50

Session I (C). New Disease Entity in Thoracic Malignancy

Chair: Anja Roden (Mayo Clinic, USA), Mee Sook Roh (Dong-A Univ.)

08:50-09:10

Update on WHO Classification of Thoracic Tumors

Dong Hoon Shin (Pusan National Univ.)

09:10-09:30

Update on WHO Classification of Thymic Tumors

Anja Roden (Mayo Clinic, USA)

09:30-09:50

Thoracic SMARCA4-Deficient Undifferentiated Tumors

Akihiko Yoshida (National Cancer Center Hospital, Japan)

09:50-10:00

Coffee Break

10:00-11:00

Session II (C). Special Session: IASLC and KALC

Chair: Young Tae Kim (Seoul National Univ.)

10:00-10:25

IASLC and Future Lung Cancer Research

Karen Kelly (Univ. of California, Davis, USA & President IASLC)

10:25-10:50

KALC and Future Lung Cancer Research

Myung-Ju Ahn (Sungkyunkwan Univ., Korea & Chairman of KALC)

10:50-11:00

Discussion

11:00-11:15

Coffee Break

11:15-11:55

Plenary Session

Chair: Myung-Ju Ahn (Sungkyunkwan Univ.)

11:15-11:55

Identifying Predictive Biomarkers of Response to Checkpoint Inhibitors in NSCLC

Justin F Gainor (Massachusetts General Hospital, USA)

11:55-12:35

Luncheon Symposium I. [MSD]

Chair: Sang-We Kim (Univ. of Ulsan)

11:55-12:35

Long-Term Benefit and Beyond Current Role of Pembrolizumab Combination in Lung Cancer

James Chih-Hsin Yang (National Taiwan Univ., Taiwan)

12:35-12:50

Coffee break

12:50-14:10

Session III (C). Environmental Lung Cancer

Chair: Paul Demers (Univ. of Toronto, Canada), Jeong Eun Lee (Chungnam National Univ.)

12:50-13:15

Public Health Interventions to Prevent Occupational Lung Cancer

Eun-A Kim (Occupational Safety and Health Research Institute)

13:15-13:40

Environmental Lung Carcinogens

Paul Demers (Univ. of Toronto, Canada)

13:40-14:05

The Decision Process for Occupational Lung Cancer

Jun-Pyo Myong (The Catholic Univ. of Korea)

14:05-14:10

Discussion

14:10-14:20

Coffee break

14:20-15:40

Session IV (C). Oral Presentation II

Chair: Gong Yong Jin (Jeonbuk National Univ.), Junghee Lee (Sungkyunkwan Univ.)

14:20-14:30

Establishment of a Small Cell Lung Cancer Mouse Model Using Enhanced Cancer Stem Cell-Functioning 3D SCLC Spheroids

Hye Seon Kang (The Catholic Univ. of Korea)

14:30-14:40

Assessment of Tumor Mutation Burden (TMB) Based on Whole Exome Sequencing Using Extracellular Vesicles-Derived DNA Obtained from Bronchoalveolar Lavage Fluid (BALF) in Advanced NSCLC Patients Treated with Pembrolizumab

Heejoung Kim (Konkuk Univ.)

14:40-14:50

A Pilot Study for Pathway Analysis and Biomarker Discovery of EGFR-TKI Response in Filipino NSCLC Patients through Untargeted Metabolomics

Maria Karmella Apaya (West Visayas State Univ., Philippines)

14:50-15:00

Major Pathologic Response after Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Interobserver Reproducibility and Its Prognostic Impact

Sungjin Kim (Seoul National Univ.)

15:00-15:10

Dual Inhibitory Effects of Resveratrol in Tobacco-Carcinogen Induced Lung Cancer Via Down-Regulation of PI3K/Akt/mTOR Pathway

Vikas Kumar (Sam Higginbottom Univ. of Agriculture, Technology & Sciences, India)

15:10-15:20

Investigating the Impact of Smoke Extract on Pulmonary Epithelial and Lung Cancer Cells Using 2D, 3D Cell Culture, and Organoid Models

Chaeuk Chung (Chungnam National Univ..)

15:20-15:30

In Silico Approach in Discovery of Potential Natural Small Molecules as Immune Checkpoint Inhibitor Therapy in NSCLC

Reny Rosalina (Palangka Raya Univ., Indonesia)

15:30-15:40

Single Cell RNA Sequencing Reveals T Cell/Myeloid Cell Interaction in both Murine and Human Lung Cancer Datasets

Duk Ki Kim (Chungnam National Univ.)

15:40-15:50

Coffee break

15:50-16:20

Satellite Symposium II (C). [Merck]

Chair: Ji-Youn Han (National Cancer Center)

15:50-16:20

METIME with VISION : Navigating the Optimal Treatment Journey for Patients with MET Exon 14 Skipping Mutation

Hyun Ae Jung (Sungkyunkwan Univ.)

ROOM D

12:50-14:10

Session III (D). Joint Symposium with HIRA (*K) Value Assessment and Approval of New Anticancer Drugs

Chair: Hye Ryun Kim (Yonsei Univ.), Ho Yun Lee (Sungkyunkwan Univ.)

12:50-13:15

Differences in the Evaluation and Approval of New Anticancer Drugs between Korean and Foreign Regulatory Authorities

Jin Hyoung Kang (The Catholic Univ. of Korea)

13:15-13:55

Establishment of Health Insurance Reimbursement Criteria and the Process of Insurance Listing for New Drugs

Jun Ho Jang (HIRA)

13:55-14:10

Discussion